# A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)

> **NCT04778800** · NA · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 60 (estimated)

## Conditions studied

- NSCLC
- Brain Metastases
- Leptomeningeal Metastasis

## Interventions

- **DRUG:** almonertinib
- **DRUG:** LM-first line treatment
- **DRUG:** LM-second line treatment

## Key facts

- **NCT ID:** NCT04778800
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-20
- **Primary completion:** 2023-02-20
- **Final completion:** 2024-02-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04778800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04778800, "A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04778800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*